Une vision stratégique de l'actualité scientifique et technologique du secteur des biotechnologies.
A LA UNE
Figures - Biotechnologies & Health in Japan
Japan Gross Domestic Product 2016 was about $4.9 trillions (7.97 % of the world economy). –Japan has been ranked 16th by the Global Innovation Index 2016: • 9th for the proportion of researchers in general population: 5.4 for 1.000 inhabitants • 15th for academia/industry cooperation • 3rd for its R&D intensity : 3.59% of its [...]
Figures - Biotechnologies & Health in Japan
A LA UNE
The biotechnology sector in Japan
With a tradition of fermentation and a strong dependence on imports of food, oil and industrial feedstock, Japan became interested very early on in the potential that biotechnology offered. As early as the 1970s, the Japanese Ministry of International Trade and Industry stated its intent to place the development of life sciences and biotechnology at [...]
The biotechnology sector in Japan
A LA UNE
CELLforCURE, a feedback on Japan
CELLforCURE is a pharmaceutical company specialized in the industrial production of cell and gene therapy medicines. Founded in 2010, it operates since 2013 Europe’s leading industrial platform in terms of capacity. CELLforCURE has operated as a CDMO with several Japanese companies since its creation. Interview with Sébastien Renouf, Director of Pharmaceutical Affairs and Deputy Managing [...]
CELLforCURE, a feedback on Japan
A LA UNE
Japanese Life Sciences research and innovation ecosystem
Not unlike France, Japan is struggling to value its academic research, despite its high quality. While its strong industrial research is still reluctant to open up to external influences, the public and private sectors are well aware of the importance of developing a more collaborative research practice.
Japanese Life Sciences research and innovation ecosystem
A LA UNE
AMED, for a better allocation of research ressources
AMED, the Japan Agency for Medical Research and Development, has been created in April 2015 to provide a unified funding allocation for medical research expenses which were previously scattered between MEXT, MHLW and METI. This unifying action aims at optimizing resources distribution to establish and maintain coherent research environments throughout Japan.
AMED, for a better allocation of research ressources

Osaka CCI action for pharma, health and MD sectors

Interview of Junichi Azuma, Osaka CCI Life Science Promotion Created in 1878, the Osaka Chamber of Commerce and Industry is the second oldest in Japan and has about 30 000 members. Its Life Science Industry Committee focuses on 3 segments: pharmaceutical, healthcare and health food, medical devices. What are the initiatives of Osaka CCI in […]

Feedback on the Japan 2016 business mission

Simon Gudin, SMEs Development Manager at LyonBiopôle. The Japanese healthcare market, the second largest in the world after the United States, is also very dynamic, with a recent opening of Japanese Pharma to Open innovation and the search for new solutions worldwide. It is therefore a target market for Lyonbiopôle, its European partners in bioXclusters […]

Vitagora has developed well in Asia

Interview with Christophe Breuillet, Director of Vitagora Can you give us a short description of Vitagora? Vitagora is a French agri-food innovation cluster, active throughout the value chain from farm to plate. Created in 2005, it now involves more than 340 actors. Due to common values around food, Vitagora has developed well in Asia, especially […]

A life sciences hub in the heart of Tokyo

In March 2016, Mitsui Fudosan launched LINK-J, a life science innovation platform, to capitalize on the historic concentration of pharmaceutical companies in Nihonbashi’s neighborhood.

Regulaxis anticipe la Phase II du traitement de l’arthrose du genou au stade précoce

    Lauréat de la phase 2 du SME/H2020 qui finance la phase I d’essai clinique de la molécule REG-O3, Regulaxis prévoit la suite. Une levée de fonds est en cours. « Nous avons remporté la seconde partie du programme SME-Inst/H2020 financé à hauteur de 2,1 millions d’euros» annonce non sans fierté Claude Carelli, le PDG […]

Japan, a giant under mutation

Despite recently ranked 9th in the annual global competitiveness list of the World Economic Forum in Davos, Japan is undergoing a profound challenge to its economic model. Its keirestu – conglomerates of diverse businesses linked together by a dense network of financial and executive interests – once the driving force of its economy, have begun […]

Euglena, from algae to food, biofuel and beyond

Exploiting the huge versatility of Euglena gracilis compounds, Euglena Corporation is mass producing algae based products, attempting to create a carbon cycling society in the process. In 1998, Mitsuru Izumo, at that time a first-year student at the University of Tokyo (Todai), went to Bangladesh. His first encounter with poverty and malnutrition sparked his will to […]

Cellules-souches : nous devons poursuivre les recherches

En partenariat avec RTFlash Vendredi, 13/10/2017  Version PDF zoom Il y a presque 20 ans, les équipes de recherche de James Alexander Thomson, Joseph Istkovitz-Eldor et Benjamin Reubinoff, parvenaient à  produire les premières lignées de cellules-souches embryonnaires chez l’homme, faisant entrer la médecine dans une nouvelle ère, celle de la médecine régénérative, capable potentiellement de […]

Biotechinfo – N°67

Le Japon, géant en mutation

Tout récemment classé 9e au palmarès annuel de la compétitivité mondiale du Forum économique mondial de Davos, le Japon traverse cependant une profonde remise en question de son modèle économique. Ses keirestu – des conglomérats d’entreprises diverses liées par un réseau dense d’intérêts financier et exécutifs –, autrefois moteur de son économie, ont en effet […]

Dernière Lettre parue

Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)
Cliquez sur l'image pour accéder à la lecture via Calaméo (accès réservé aux abonnés)

Abonnement

(abonnement aux éditions de la Lettre et accès intégral au site)

Abonnez-vous à notre newsletter gratuite

InnovIn Med